XML 70 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Mar. 19, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Fiscal Year Focus 2025    
Document Period End Date Dec. 31, 2025    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001709941    
Current Fiscal Year End Date --12-31    
Entity Registrant Name BIOAGE LABS, INC.    
Entity File Number 001-42279    
Document Annual Report true    
Document Transition Report false    
Entity Tax Identification Number 47-4721157    
Entity Incorporation, State or Country Code DE    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Address, Address Line One 5885 Hollis Street    
Entity Address, Address Line Two Suite 370    
Entity Address, City or Town Emeryville    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94608    
City Area Code 510    
Local Phone Number 806-1445    
Entity Shell Company false    
Trading Symbol BIOA    
Security Exchange Name NASDAQ    
Title of 12(b) Security Common Stock, par value $0.00001 per share    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Public Float     $ 112.7
Entity Common Stock, Shares Outstanding   44,379,753  
Documents Incorporated by Reference [Text Block]

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s Definitive Proxy Statement (“Proxy Statement”) relating to the 2026 Annual Meeting of Stockholders will be filed with the Commission within 120 days after the end of the Registrant’s 2025 fiscal year and are incorporated by reference into Part III of this Report.

 

Auditor Firm ID:185

Auditor Name: KPMG LLP

Auditor Location: San Francisco, California
   
Auditor Name KPMG LLP    
Auditor Firm ID 185    
Auditor Location San Francisco, California    
Auditor Opinion

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of BioAge Labs, Inc. and subsidiary (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2025, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.